Wednesday, July 8, 2026

Patent intelligence · US

US 10696689

Somatostatin modulators and uses thereof

granted A61KA61K47/14A61K9/0014A61K9/0019
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 26
Patent details — US 10696689
Jurisdiction
US
Status
granted
Grant date
Jun 30, 2020
Expiration
Jun 25, 2040
Claims
8
CPC classes
A61K, A61K47/14, A61K9/0014, A61K9/0019
View on Google Patents ↗

Quick answer

US 10696689 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Jun 30, 2020. Expires Jun 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K47/14, A61K9/0014, A61K9/0019, A61K9/0095, A61K9/06

More from CRINETICS PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12280046

    Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

    CRINETICS PHARMACEUTICALS, INC. · Expires Apr 17, 2045

    granted
  2. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    CRINETICS PHARMACEUTICALS, INC. · Expires Jan 23, 2045

    granted
  3. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Expires Oct 31, 2044

    granted
  4. US 11957674

    Formulations of a somatostatin modulator

    CRINETICS PHARMACEUTICALS, INC. · Expires Apr 11, 2044

    granted
  5. US 11834462

    Somatostatin modulators and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Expires Nov 30, 2043

    granted
  6. US 11773076

    Crystalline forms of a somatostatin modulator

    CRINETICS PHARMACEUTICALS, INC. · Expires Sep 28, 2043

    granted
  7. US 11608335

    Somatostatin modulators and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Expires Mar 16, 2043

    granted
  8. US 11566015

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    CRINETICS PHARMACEUTICALS, INC. · Expires Jan 26, 2043

    granted

Frequently asked questions

What is US patent 10696689?

US 10696689 (Somatostatin modulators and uses thereof) is held by CRINETICS PHARMACEUTICALS, INC.. Status: granted. Granted Jun 30, 2020. Expires Jun 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10696689?

CRINETICS PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 10696689 expire?

Our index shows an expiration date of Jun 25, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.